These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 20976576)
21. Sublingual Immunotherapy: Past, present, paradigm for the future? A review of the literature. Leatherman BD; Owen S; Parker M; Chadwick S; Fornadley JA; Colson D; Fass P Otolaryngol Head Neck Surg; 2007 Mar; 136(3 Suppl):S1-20. PubMed ID: 17321336 [TBL] [Abstract][Full Text] [Related]
22. Risk management and intrusions on medical practice: striking a balance. Enzi MB; Kennedy EM Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743 [TBL] [Abstract][Full Text] [Related]
23. Assessing potential risks and evaluating expected benefits. Shaya FT; Gu A Manag Care Interface; 2005 May; 18(5):27-30. PubMed ID: 15941187 [TBL] [Abstract][Full Text] [Related]
24. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Novak E; Allen PJ Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005 [TBL] [Abstract][Full Text] [Related]
25. Regulation of allergenic products in the United States: the promise and problem of adjuvants in allergen immunotherapy. Rabin RL Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():219-22; discussion 223. PubMed ID: 20799464 [No Abstract] [Full Text] [Related]
26. The history of sublingual immunotherapy. Pajno GB; Barberi S Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):1-3. PubMed ID: 19944001 [TBL] [Abstract][Full Text] [Related]
27. Uses of drugs not described in the package insert (off-label uses). Committee on Drugs. American Academy of Pediatrics Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968 [TBL] [Abstract][Full Text] [Related]
28. [Allergens for specific immunotherapy: authorization and quality criteria of the Paul-Ehrlich-Institut]. May S; Kaul S; Schröder C; Vieths S Hautarzt; 2006 Oct; 57(10):867-74. PubMed ID: 16977441 [TBL] [Abstract][Full Text] [Related]
29. A bright future for sublingual immunotherapy?--pro. Bousquet J Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):237-41. PubMed ID: 17393745 [No Abstract] [Full Text] [Related]
33. Specific immunotherapy for food allergy: basic principles and clinical aspects. Enrique E; Cisteró-Bahíma A Curr Opin Allergy Clin Immunol; 2006 Dec; 6(6):466-9. PubMed ID: 17088653 [TBL] [Abstract][Full Text] [Related]
34. Sublingual immunotherapy in children--ready for prime time? Wahn U; Malling HJ; Kleine-Tebbe J Pediatr Allergy Immunol; 2010 Jun; 21(4 Pt 1):559-63. PubMed ID: 20636895 [No Abstract] [Full Text] [Related]
35. The use of standardized extracts in allergen immunotherapy. Nelson HS J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):41-5. PubMed ID: 10887303 [TBL] [Abstract][Full Text] [Related]
36. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Cox L; Calderon MA Curr Med Res Opin; 2010 Dec; 26(12):2723-33. PubMed ID: 20979432 [TBL] [Abstract][Full Text] [Related]
37. Medical judgment and therapeutics. Somberg JC Am J Ther; 1999 Nov; 6(6):291-2. PubMed ID: 11329111 [No Abstract] [Full Text] [Related]